NYMC Faculty Publications
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline
Author Type(s)
Faculty
DOI
10.1093/ofid/ofaf615
Journal Title
Open Forum Infectious Diseases
Document Type
Article
Publication Date
11-1-2025
Department
Medicine
Keywords
bictegravir, clinical trial, complex antiretroviral regimens, HIV-1, lenacapavir
Disciplines
Medicine and Health Sciences
Abstract
ARTISTRY-1 is a phase 2/3 trial of bictegravir (BIC; 75 mg) plus lenacapavir (LEN; 25 mg or 50 mg) versus complex antiretroviral therapy regimens in 128 virologically suppressed people with HIV-1. At 48 weeks, BIC + LEN (at either LEN dose) was highly effective at maintaining virologic suppression and was well tolerated.
Recommended Citation
Mounzer, K., Slim, J., Ramgopal, M., Hedgcock, M., Bloch, M., Santana, J., Aizen, K., Zhang, X., Sklar, P., Montezuma-Rusca, J., & Segal-Maurer, S. (2025). Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline. Open Forum Infectious Diseases, 12 (11). https://doi.org/10.1093/ofid/ofaf615
